- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03496415
The Neuroprotective Effect of Remote Ischemic Conditioning in Aneurysm Coiling Therapy (NEAT)
November 21, 2018 updated by: Ji Xunming,MD,PhD, Capital Medical University
The Neuroprotective Effect of Remote Ischemic Conditioning in Aneurysm Coiling
The overall incidence of DWI positive for thromboembolic events following endovascular treatment of intracranial aneurysms is proximately 50%.
Whether remote ischemic conditioning was safe and effective to reduce ischemic brain lesions on DWI after endovascular treatment of intracranial aneurysms is still unclear.
The investigators' hypothesis is that remote ischemic conditioning is a safe and effective strategy to reduce new ischemic lesions in intracranial aneurysms patients undergoing endovascular treatment.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
210
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nanyang, China
- Recruiting
- Nanyang City Center Hospital
-
Zhengzhou, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
-
An Hui
-
Suzhou, An Hui, China
- Recruiting
- Suzhou Municipal Hoapital
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Not yet recruiting
- Xuanwu Hospital, Capital Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- Not yet recruiting
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
-
Contact:
- Dongsheng Guan
-
-
Shandong
-
Dongying, Shandong, China, 257034
- Recruiting
- Shengli Oilfield Center Hospital
-
Contact:
- Zongen Gao, MD
- Phone Number: 8613854669979
- Email: gaozongen@126.com
-
Contact:
- Tianping Tang, MD
- Phone Number: 8618678662921
- Email: 18678662921@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 years or older
- Unruptured brain aneurysm deemed suitable for neuroendovascular repair
- Normal baseline brain MRI
- Female subjects of childbearing potential have a negative pregnancy test.
- Signed informed consent prior to entering study
Exclusion Criteria:
- Dissecting or mycotic brain aneurysm.
- Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment
- Severe, sustained hypertension (SBP > 185 mmHg or DBP > 110 mmHg)
- Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs
- Pre-morbid modified Rankin scale score of greater than 1
- Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations
- Patients who are unable to have an MRI scan for any reason.
- Currently participating or previously participated in any investigational drug or device study within 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Remote ischemic conditioning
|
Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
|
SHAM_COMPARATOR: Sham remote ischemic conditioning
|
sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The presence of ≥1 new brain lesions on DWI
Time Frame: within 72 hours after endovascular treatment
|
Assessed by DWI
|
within 72 hours after endovascular treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of new ischemic lesions
Time Frame: within 72 hours after endovascular treatment
|
within 72 hours after endovascular treatment
|
|
Volume of new ischemic lesions
Time Frame: within 72 hours after endovascular treatment
|
within 72 hours after endovascular treatment
|
|
National Institutes of Health Stroke Scale
Time Frame: 7 days or discharge
|
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.
|
7 days or discharge
|
Cerebrovascular events
Time Frame: 30 days
|
Cerebrovascular events included ischemic stroke, hemorrhagic stroke, and TIA.
|
30 days
|
Nondisabling events
Time Frame: 30 days
|
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.National Institutes of Health Stroke Scale ≤3 or TIA is defined as nondisabling events
|
30 days
|
Modified Rankin Scale
Time Frame: 30 days
|
Scores on the modified Rankin scale of functional disability range from 0 (no symptoms) to 6 (death).
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events and serious adverse events
Time Frame: 30 days
|
Occurrence of adverse events and serious adverse events
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 3, 2018
Primary Completion (ANTICIPATED)
December 1, 2018
Study Completion (ANTICIPATED)
January 1, 2019
Study Registration Dates
First Submitted
March 22, 2018
First Submitted That Met QC Criteria
April 11, 2018
First Posted (ACTUAL)
April 12, 2018
Study Record Updates
Last Update Posted (ACTUAL)
November 23, 2018
Last Update Submitted That Met QC Criteria
November 21, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-NEAT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysm
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
IRCCS San RaffaeleCompletedAneurysm Thoracic | Aneurysm Abdominal | Renal AneurysmUnited States, France, Italy, United Kingdom, Germany, Spain, Denmark, Sweden
-
CEVARIIUniversity of Colorado, Denver; University of Copenhagen; University of Iowa; University... and other collaboratorsEnrolling by invitationComplex EVAR in Inflammatory and Infective Abdominal and Thoracoabdominal Aortic Aneurysms (CEVARII)Abdominal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Aneurysm, Infected | Inflammatory Abdominal Aortic Aneurysm | Aneurysm, MycoticUnited States
-
Cook Research IncorporatedCompletedAbdominal Aortic Aneurysm (AAA) | Aorto-iliac Aneurysm | Juxtarenal AneurysmUnited States
-
JOTEC GmbHRecruiting
-
The Christ HospitalMedtronicRecruiting
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
IRCCS San RaffaeleCompletedAneurysm | Aneurysm Thoracic | Aneurysm Abdominal | Aneurysm, Thoracoabdominal AorticItaly
-
Petrovsky National Research Centre of SurgeryRecruitingAorta Abdominalis; Aneurysm | Aorta Thoracic; AneurysmRussian Federation
Clinical Trials on remote ischemic conditioning
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; University Medical Center Groningen and other collaboratorsUnknownKidney Transplantation | Acute Kidney Injury | Glomerular Filtration Rate | Delayed Graft FunctionNetherlands, Denmark, Sweden
-
Yi YangRecruiting
-
University of ArizonaRecruitingBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain TraumaUnited States
-
Grethe AndersenCompletedCerebrovascular Disorders | Central Nervous System Diseases | Ischemic Stroke | Stroke, AcuteDenmark
-
Rutgers, The State University of New JerseyUnknownLiver Diseases | Urologic Diseases | Pancreatic Diseases | Complication of Surgical Procedure | Laparotomy | Laparoscopy | Gastrointestinal Disease | Retroperitoneal Disease | Pelvis DiseaseUnited States
-
Capital Medical UniversityUnknownAneurysm, Ruptured | Coiling TherapyChina
-
Capital Medical UniversityRecruiting
-
Yi YangRecruitingAcute Ischemic StrokeChina
-
Yi YangRecruitingEssential HypertensionChina
-
Yi YangRecruitingIntracranial HemorrhagesChina